191 related articles for article (PubMed ID: 32234730)
1. Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'.
De Falco V; Poliero L; Vitello PP; Ciardiello D; Vitale P; Zanaletti N; Giunta EF; Terminiello M; Caputo V; Carlino F; Di Liello R; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Orditura M; De Vita F; Fasano M; Napolitano S; Martini G; Della Corte CM; Franco R; Altucci L; Ciardiello F; Troiani T
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32234730
[TBL] [Abstract][Full Text] [Related]
2. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience.
Caputo V; De Falco V; Ventriglia A; Famiglietti V; Martinelli E; Morgillo F; Martini G; Corte CMD; Ciardiello D; Poliero L; De Vita F; Orditura M; Fasano M; Franco R; Caraglia M; Avitabile A; Scalamogna R; Marchi B; Ciardiello F; Troiani T; Napolitano S
Ther Adv Med Oncol; 2022; 14():17588359221096878. PubMed ID: 35547096
[TBL] [Abstract][Full Text] [Related]
4. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.
Cho M; Ahn S; Hong M; Bang H; Van Vrancken M; Kim S; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Sun JM; Lee SH; Ahn MJ; Park K; Kim DH; Lee S; Park W; Kim KM
Oncotarget; 2017 Jun; 8(26):42478-42486. PubMed ID: 28477007
[TBL] [Abstract][Full Text] [Related]
5. Effect of a Collaboration Between a Health Plan, Oncology Practice, and Comprehensive Genomic Profiling Company from the Payer Perspective.
Reitsma M; Fox J; Borre PV; Cavanaugh M; Chudnovsky Y; Erlich RL; Gribbin TE; Anhorn R
J Manag Care Spec Pharm; 2019 May; 25(5):601-611. PubMed ID: 30632889
[TBL] [Abstract][Full Text] [Related]
6. Current practice of genomic profiling of patients with advanced solid tumours in Italy: the Italian Register of Actionable Mutations (RATIONAL) study.
Normanno N; De Luca A; Abate RE; Morabito A; Milella M; Tabbò F; Curigliano G; Masini C; Marchetti P; Pruneri G; Guarneri V; Frassineti GL; Fasola G; Adamo V; Daniele B; Berardi R; Feroce F; Maiello E; Pinto C
Eur J Cancer; 2023 Jul; 187():174-184. PubMed ID: 37167765
[TBL] [Abstract][Full Text] [Related]
7. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
[TBL] [Abstract][Full Text] [Related]
8. Correction:
ESMO Open; 2020 May; 5(3):e000675corr1. PubMed ID: 32424066
[No Abstract] [Full Text] [Related]
9. Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.
Milbury CA; Creeden J; Yip WK; Smith DL; Pattani V; Maxwell K; Sawchyn B; Gjoerup O; Meng W; Skoletsky J; Concepcion AD; Tang Y; Bai X; Dewal N; Ma P; Bailey ST; Thornton J; Pavlick DC; Frampton GM; Lieber D; White J; Burns C; Vietz C
PLoS One; 2022; 17(3):e0264138. PubMed ID: 35294956
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy comprehensive genomic profiling of lung cancer in the Italian population: A real-world experience.
Porta C; Pradelli L; Sicari E; Castellani S; Sivakumar S; Sokol E; Montesion M; Wieland T; Rambichler J; Minari R; Tiseo M
Lung Cancer; 2023 Nov; 185():107359. PubMed ID: 37703610
[TBL] [Abstract][Full Text] [Related]
11. First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities.
Matsubara J; Mukai K; Kondo T; Yoshioka M; Kage H; Oda K; Kudo R; Ikeda S; Ebi H; Muro K; Hayashi R; Tokudome N; Yamamoto N; Muto M
JAMA Netw Open; 2023 Jul; 6(7):e2323336. PubMed ID: 37459099
[TBL] [Abstract][Full Text] [Related]
12. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
[TBL] [Abstract][Full Text] [Related]
13. The emerging clinical relevance of genomic profiling in neuroendocrine tumours.
Burak GI; Ozge S; Cem M; Gulgun B; Zeynep DY; Atil B
BMC Cancer; 2021 Mar; 21(1):234. PubMed ID: 33676450
[TBL] [Abstract][Full Text] [Related]
14. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing.
Cai H; Jing C; Chang X; Ding D; Han T; Yang J; Lu Z; Hu X; Liu Z; Wang J; Shang L; Wu S; Meng P; Lin L; Zhao J; Nie M; Yin K
J Transl Med; 2019 Jun; 17(1):189. PubMed ID: 31164161
[TBL] [Abstract][Full Text] [Related]
15. Role of Tumor Molecular Profiling With FoundationOne®CDx in Advanced Solid Tumors: A Single-Centre Experience From Romania.
Popa AM; Stejeroiu MA; Iaciu C; Olaru M; Orlov Slavu C; Parosanu A; Stanciu IM; Pirlog C; Pavel S; Nitipir C
Cureus; 2023 Dec; 15(12):e50709. PubMed ID: 38111812
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
17. Current Clinical Practice of Precision Medicine Using Comprehensive Genomic Profiling Tests in Biliary Tract Cancer in Japan.
Kanai M
Curr Oncol; 2022 Sep; 29(10):7272-7284. PubMed ID: 36290850
[TBL] [Abstract][Full Text] [Related]
18. Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
Gonçalves A; Bertucci F; Guille A; Garnier S; Adelaide J; Carbuccia N; Cabaud O; Finetti P; Brunelle S; Piana G; Tomassin-Piana J; Paciencia M; Lambaudie E; Popovici C; Sabatier R; Tarpin C; Provansal M; Extra JM; Eisinger F; Sobol H; Viens P; Lopez M; Ginestier C; Charafe-Jauffret E; Chaffanet M; Birnbaum D
Oncotarget; 2016 Nov; 7(48):79428-79441. PubMed ID: 27765906
[TBL] [Abstract][Full Text] [Related]
19. [Feasibility of amplicon-based targeted next-generation sequencing of colorectal cancer in endoscopic biopsies].
Wang YJ; Jiang RR; Liu HJ; Zhang B; Ye F; Bu H
Zhonghua Bing Li Xue Za Zhi; 2018 Jul; 47(7):499-504. PubMed ID: 29996313
[No Abstract] [Full Text] [Related]
20. Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients.
Falcone R; Lombardi P; Filetti M; Fabi A; Altamura V; Scambia G; Daniele G
Curr Oncol; 2023 Feb; 30(2):2501-2509. PubMed ID: 36826152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
